Investigating the Association Between Steatotic Liver Disease and CKD in a Nationally Representative Sample

Overview

Journal Kidney360

Specialty Nephrology

Date 2024 Sep 5

PMID 39235870

Authors

Mason Lai

Jennifer C Lai

Andrew S Allegretti

Kavish R Patidar

Giuseppe Cullaro

Affiliations

Soon will be listed here.

Citing Articles

Curvilinear association between Framingham Steatosis Index and chronic kidney disease: a nationwide cross-sectional study.

Jiang C, Wang B, Wang J, Qu Y, Zhang X Front Med (Lausanne). 2025; 11:1518202.

PMID: 39876873 PMC: 11772482. DOI: 10.3389/fmed.2024.1518202.

References

Koehler E, Schouten J, Hansen B, Hofman A, Stricker B, Janssen H . External validation of the fatty liver index for identifying nonalcoholic fatty liver disease in a population-based study. Clin Gastroenterol Hepatol. 2013; 11(9):1201-4. DOI: 10.1016/j.cgh.2012.12.031. View

Inker L, Eneanya N, Coresh J, Tighiouart H, Wang D, Sang Y . New Creatinine- and Cystatin C-Based Equations to Estimate GFR without Race. N Engl J Med. 2021; 385(19):1737-1749. PMC: 8822996. DOI: 10.1056/NEJMoa2102953. View

Webster A, Nagler E, Morton R, Masson P . Chronic Kidney Disease. Lancet. 2016; 389(10075):1238-1252. DOI: 10.1016/S0140-6736(16)32064-5. View

Sanyal A, Van Natta M, Clark J, Neuschwander-Tetri B, Diehl A, Dasarathy S . Prospective Study of Outcomes in Adults with Nonalcoholic Fatty Liver Disease. N Engl J Med. 2021; 385(17):1559-1569. PMC: 8881985. DOI: 10.1056/NEJMoa2029349. View

Musso G, Cassader M, Gambino R . PNPLA3 rs738409 and TM6SF2 rs58542926 gene variants affect renal disease and function in nonalcoholic fatty liver disease. Hepatology. 2014; 62(2):658-9. DOI: 10.1002/hep.27643. View

Mantovani A, Petracca G, Beatrice G, Csermely A, Lonardo A, Schattenberg J . Non-alcoholic fatty liver disease and risk of incident chronic kidney disease: an updated meta-analysis. Gut. 2020; 71(1):156-162. DOI: 10.1136/gutjnl-2020-323082. View

Sirota J, McFann K, Targher G, Chonchol M, Jalal D . Association between nonalcoholic liver disease and chronic kidney disease: an ultrasound analysis from NHANES 1988-1994. Am J Nephrol. 2012; 36(5):466-71. PMC: 3563287. DOI: 10.1159/000343885. View

de Ledinghen V, Vergniol J, Capdepont M, Chermak F, Hiriart J, Cassinotto C . Controlled attenuation parameter (CAP) for the diagnosis of steatosis: a prospective study of 5323 examinations. J Hepatol. 2014; 60(5):1026-31. DOI: 10.1016/j.jhep.2013.12.018. View

Loomba R, Sanyal A . The global NAFLD epidemic. Nat Rev Gastroenterol Hepatol. 2013; 10(11):686-90. DOI: 10.1038/nrgastro.2013.171. View

10.

Bedogni G, Bellentani S, Miglioli L, Masutti F, Passalacqua M, Castiglione A . The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol. 2006; 6:33. PMC: 1636651. DOI: 10.1186/1471-230X-6-33. View

11.

Targher G, Bertolini L, Rodella S, Zoppini G, Lippi G, Day C . Non-alcoholic fatty liver disease is independently associated with an increased prevalence of chronic kidney disease and proliferative/laser-treated retinopathy in type 2 diabetic patients. Diabetologia. 2007; 51(3):444-50. DOI: 10.1007/s00125-007-0897-4. View

12.

Byrne C, Targher G . NAFLD as a driver of chronic kidney disease. J Hepatol. 2020; 72(4):785-801. DOI: 10.1016/j.jhep.2020.01.013. View

13.

Inker L, Astor B, Fox C, Isakova T, Lash J, Peralta C . KDOQI US commentary on the 2012 KDIGO clinical practice guideline for the evaluation and management of CKD. Am J Kidney Dis. 2014; 63(5):713-35. DOI: 10.1053/j.ajkd.2014.01.416. View

14.

Fang M, Wang D, Coresh J, Selvin E . Trends in Diabetes Treatment and Control in U.S. Adults, 1999-2018. N Engl J Med. 2021; 384(23):2219-2228. PMC: 8385648. DOI: 10.1056/NEJMsa2032271. View

15.

Tsochatzis E, Gurusamy K, Ntaoula S, Cholongitas E, Davidson B, Burroughs A . Elastography for the diagnosis of severity of fibrosis in chronic liver disease: a meta-analysis of diagnostic accuracy. J Hepatol. 2010; 54(4):650-9. DOI: 10.1016/j.jhep.2010.07.033. View

16.

Sasso M, Miette V, Sandrin L, Beaugrand M . The controlled attenuation parameter (CAP): a novel tool for the non-invasive evaluation of steatosis using Fibroscan. Clin Res Hepatol Gastroenterol. 2011; 36(1):13-20. DOI: 10.1016/j.clinre.2011.08.001. View

17.

Tilg H, Byrne C, Targher G . NASH drug treatment development: challenges and lessons. Lancet Gastroenterol Hepatol. 2023; 8(10):943-954. DOI: 10.1016/S2468-1253(23)00159-0. View

18.

Targher G, Mantovani A, Alisi A, Mosca A, Panera N, Byrne C . Relationship Between PNPLA3 rs738409 Polymorphism and Decreased Kidney Function in Children With NAFLD. Hepatology. 2019; 70(1):142-153. DOI: 10.1002/hep.30625. View

19.

Marzuillo P, Di Sessa A, Guarino S, Capalbo D, Umano G, Pedulla M . Nonalcoholic fatty liver disease and eGFR levels could be linked by the PNPLA3 I148M polymorphism in children with obesity. Pediatr Obes. 2019; 14(10):e12539. DOI: 10.1111/ijpo.12539. View

20.

Kibria G, Crispen R . Prevalence and trends of chronic kidney disease and its risk factors among US adults: An analysis of NHANES 2003-18. Prev Med Rep. 2020; 20:101193. PMC: 7578737. DOI: 10.1016/j.pmedr.2020.101193. View